Darbinurad

Darbinurad
Clinical data
Other names	D-0120
Identifiers
	IUPAC name 2-[1-[[3-(4-cyanophenyl)pyridin-4-yl]sulfanylmethyl]cyclopropyl]acetic acid;
CAS Number	1877347-38-0;
PubChem CID	118902135;
ChemSpider	128992995;
UNII	AYFFM7L5F0;
Chemical and physical data
Formula	C18H16N2O2S
Molar mass	324.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC1(CC(=O)O)CSC2=C(C=NC=C2)C3=CC=C(C=C3)C#N;
	InChI InChI=InChI=1S/C18H16N2O2S/c19-10-13-1-3-14(4-2-13)15-11-20-8-5-16(15)23-12-18(6-7-18)9-17(21)22/h1-5,8,11H,6-7,9,12H2,(H,21,22); Key:RHASGUGQMCVYMQ-UHFFFAOYSA-N;

Darbinurad is a investigational new drug that is being evaluated for the treatment of gout. It is a selective urate transporter 1 (URAT1) inhibitor that blocks the reabsorption of uric acid within the renal proximal tubule, thereby reducing serum uric acid concentrations.^[1]^[2]

References

^ Kaufmann D, Chaiyakunapruk N, Schlesinger N (November 2024). "Optimizing gout treatment: A comprehensive review of current and emerging uricosurics". Joint Bone Spine. 92 (2): 105826. doi:10.1016/j.jbspin.2024.105826. PMID 39622367.
^ "Darbinurad". PatSnap.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.